Free shipping for any 2 packs purchased
Welcome to the ultimate guide to the Medtronic MiniMed 780G, a groundbreaking insulin pump system revolutionizing the lives of individuals with type 1 diabetes. The Medtronic MiniMed 780G is revolutionizing the standards of diabetes management with its groundbreaking technology. In this comprehensive guide, we delve into the critical features of this revolutionary device, discussing its unique advantages, competition and its potential to reshape the future of insulin pump technology.
As the newest member of the esteemed Medtronic series the MiniMed 780G aims to elevate the lives of people with diabetes. This advanced system combines an insulin pump, a continuous glucose monitor (CGM) and intelligent algorithms in a hybrid closed-loop design.
Moving past conventional insulin pump methods the MiniMed 780G incorporates the innovative SmartGuard algorithm. This feature constantly analyzes CGM data, making real-time adjustments to both basal and bolus insulin dosages. This automation sets the MiniMed 780G apart as a top contender in the insulin pump market. A distinguishing feature of the MiniMed 780G is its state-of-the-art meal-detection technology. By recognizing when the user is eating the system adjusts insulin delivery to match carbohydrate intake. This removes the necessity for manual carbohydrate calculations and advances us towards a more automated and hands-free diabetes management system.
The MiniMed 780G has undergone rigorous clinical evaluations to confirm its safety and efficacy. The device demonstrates significant improvements in time spent within the targeted glucose range, while also reducing the risk of hypoglycemia. Users consistently report increased overall satisfaction and a heightened sense of control in their diabetes management.
The MiniMed 780G empowers individuals with type 1 diabetes by offering greater flexibility and enhancing their quality of life. It instills a newfound confidence in managing the condition, paving the way for a less restrictive lifestyle. This device’s various features and benefits highlight its potential to bring transformative changes to diabetes care.
The upcoming release of the Medtronic MiniMed 780G has already sparked excitement within the diabetes community. Medtronic has announced that pre-orders for the 780G will commence on May 15, 2023, with nationwide delivery expected later in the summer. This is an exciting development for those awaiting this cutting-edge technology, underlining Medtronic’s ongoingmcommitment to innovation in diabetes management.
Indeed the Medtronic MiniMed 780G has received FDA approval. The U.S. Food and Drug Administration granted approval on April 21, 2023, marking a significant milestone in diabetes care. This endorsement ensures that the MiniMed 780G meets stringent FDA standards for safety
and effectiveness, providing those with type 1 diabetes a reliable and advanced option for insulin delivery.
Gaining FDA approval is a challenging endeavor that entails a thorough evaluation process. This stamp of approval serves as a testament to the MiniMed 780G’s reliability and capability, reinforcing its position as a breakthrough in diabetes care technology.
Obtaining FDA approval for a medical device is no easy feat, as it involves a rigorous evaluation process. The MiniMed 780G from Medtronic has successfully undergone this scrutiny, proving its effectiveness and commitment to the highest standards of quality and safety. The FDA
approval of the MiniMed 780G was based on a clinical trial involving 157 participants with type 1 diabetes. This trial demonstrated the system’s ability to increase time in range (TIR) and reduce hypoglycemia when compared to sensor-augmented pump therapy. With customizable
basal insulin delivery and automatic correction boluses the MiniMed 780G empowers individuals to keep their glucose levels in check. The FDA’s stamp of approval further solidifies the MiniMed 780G’s position as a reliable and trusted choice for diabetes management.
It’s worth noting that while the MiniMed 780G is FDA-approved, it may not be available in all countries or regions. People with diabetes need to consult with their healthcare providers and/or local Medtronic representatives to determine the availability of the MiniMed 780G in their area.
The MiniMed 780G is an advanced insulin pump system designed to assist individuals with type 1 diabetes in managing their blood glucose levels effectively. Equipped with innovative features the MiniMed 780G aims to offer users enhanced convenience, flexibility and optimized glucose management. Below are some of its standout features:
What is a Closed-Loop System?
Imagine a diabetes management system that works seamlessly, like a well-oiled machine. That’s precisely what the Medtronic 780G offers. A closed-loop system, also known as an automated insulin delivery system, combines the power of an insulin pump and a continuous glucose monitor (CGM) to create a harmonious feedback loop. The CGM continuously measures glucose levels, while the insulin pump adjusts the insulin delivery accordingly. This dynamic duo ensures that blood sugar levels stay within a target range, reducing the risk of highs and lows.
At the heart of the Medtronic 780G lies the ingenious SmartGuard algorithm. This advanced technology analyzes real-time data from the CGM and makes precise insulin dosage adjustments to maintain optimal glucose levels. Gone are the days of constant manual calculations and guesswork. With the closed-loop system, you can bid farewell to the stress of managing your diabetes and embrace a more automated and intuitive approach.
Living with diabetes shouldn’t mean sacrificing your lifestyle or constantly worrying about your glucose levels.
The Medtronic 780G empowers you to reclaim your freedom. Whether you’re engaging in physical activity, enjoying a meal, or even sleeping the closed-loop system tirelessly works in the background to keep your glucose levels in check. This newfound freedom allows you to focus on what truly matters – living your life to the fullest.
The Guardian Sensor is designed to provide precise and continuous glucose monitoring. This small and discreet device is your diabetes detective, constantly working to keep you informed about your glucose levels. By wearing the Guardian Sensor, you gain valuable insights that help guide your diabetes management decisions.
Accuracy is crucial when it comes to glucose monitoring and the Guardian Sensor delivers on that front. It has been rigorously tested to meet the highest standards, providing reliable and trustworthy results. With its advanced algorithms the Guardian Sensor compensates for potential variations, ensuring that you have the most accurate data at your disposal.
the Medtronic 780G and Guardian Sensor duo work hand in hand to revolutionize your diabetes management. The Guardian Sensor wirelessly transmits glucose data to the pump, enabling the SmartGuard algorithm to make precise insulin adjustments based on real-time information. This closed-loop integration ensures that your insulin delivery remains finely tuned to your glucose levels, providing stability and minimizing fluctuations. But that’s not all—the Guardian Sensor is designed with your convenience in mind. Its compact size and comfortable wearability allow you to go about your day without the burden of bulky devices or constant disruptions. With up to seven days of continuous wear, you can enjoy uninterrupted glucose monitoring.
Diabetes management in children and adolescents can be challenging, but the Medtronic 780G pump is specifically designed to simplify the process for younger individuals. With its user-friendly interface and automated features, this pump empowers children and adolescents to take an active role in their diabetes care. It provides precise insulin dosing based on real-time data, promoting stable glucose levels and reducing the risk of complications. The Medtronic 780G pump’s age-appropriate features and advanced technology make it an excellent choice for younger individuals navigating the complexities of diabetes management.
Maintaining stable blood sugar levels is crucial for adults with diabetes and the Medtronic 780G pump offers a seamless and intuitive experience. Its closed-loop system, combining an insulin pump and continuous glucose monitor, works tirelessly in the background to keep glucose levels within target ranges. With smart algorithms and automated adjustments, this pump provides adults with an extra layer of support and confidence in managing their diabetes.
For older adults, managing diabetes can present unique challenges. However, the Medtronic 780G pump is designed to simplify diabetes management and ensure safety and well-being. Its user-friendly interface and automated functions make it easier for older adults to navigate and understand their diabetes care. The pump’s advanced features, such as glucose trend insights and customizable alerts, provide valuable information to help older adults and their caregivers make informed decisions. Gifting the elderly the confidence to live life to the fullest while effectively managing their diabetes.
Maintaining stable blood sugar levels is crucial for adults with diabetes, and the Medtronic 780G pump offers a seamless and intuitive experience. Its closed-loop system, combining an insulin pump and continuous glucose monitor, works tirelessly in the background to keep glucose levels within target ranges. With smart algorithms and automated adjustments, this pump provides adults with an extra layer of support and confidence in managing their diabetes.
For older adults, managing diabetes can present unique challenges. However, the Medtronic 780G pump is designed to simplify diabetes management and ensure safety and well-being. It’s user-friendly interface and automated functions make it easier for older adults to navigate and understand their diabetes care. The pump’s advanced features, such as glucose trend insights and customizable alerts, provide valuable information to help older adults and their caregivers make informed decisions. Gifting the elderly the confidence to live life to the fullest while effectively managing their diabetes.
Do you need a CGM for the MiniMed?
The Medtronic MiniMed 780G is designed to be used as a hybrid closed-loop system which means it combines an insulin pump with CGM technology. This integration allows for a dynamic feedback loop, where the pump adjusts insulin delivery based on real-time glucose readings from the CGM. The CGM continuously measures your glucose levels, providing valuable data
The MiniMed 780G leverages this data to make automated adjustments to your insulin delivery, optimizing your basal rates and bolus doses to help you achieve more consistent glucose control and reduce the risk of hypoglycemia. Additionally the CGM system paired with the MiniMed 780G offers customizable alarms and alerts, acting as an extra layer of protection by notifying you of high or low glucose levels, allowing you to take prompt action and prevent potential complications. These advanced features work together to enhance your diabetes management experience and provide peace of mind.
Can You Use the MiniMed 780G without CGM?
Yes you can, however the Medtronic MiniMed 780G pump is specifically designed to work in conjunction with CGM technology. While it may be technically possible to use the pump without CGM, it would significantly limit the capabilities and benefits of the system. CGM plays a crucial role in providing real-time data, enabling automated adjustments and maximizing the overall performance of the MiniMed 780G.
Phones for Medtronic MiniMed 780G
The Medtronic MiniMed 780G is compatible with a broad array of smartphones, encompassing recent models from leading brands such as Apple and Samsung. This pump functions smoothly with smartphones operating on Android 7.0 and above, as well as iOS 12.2 or newer versions.
The Medtronic MiniMed 780G is designed to be used as a hybrid closed-loop system, which means it combines an insulin pump with CGM technology. This integration allows for a dynamic feedback loop, where the pump adjusts insulin delivery based on real-time glucose readings from the CGM. The CGM continuously measures your glucose levels, providing valuable data
The MiniMed 780G leverages this data to make automated adjustments to your insulin delivery, optimizing your basal rates and bolus doses to help you achieve more consistent glucose control and reduce the risk of hypoglycemia. Additionally, the CGM system paired with the MiniMed 780G offers customizable alarms and alerts, acting as an extra layer of protection by notifying you of high or low glucose levels, allowing you to take prompt action and prevent potential complications. These advanced features work together to enhance your diabetes management experience and provide peace of mind.
Yes you can, however, the Medtronic MiniMed 780G pump is specifically designed to work in conjunction with CGM technology. While it may be technically possible to use the pump without CGM, it would significantly limit the capabilities and benefits of the system. CGM plays a crucial role in providing real-time data, enabling automated adjustments, and maximizing the overall performance of the MiniMed 780G.
The Medtronic MiniMed 780G is compatible with a wide range of smartphones, including the latest models from popular brands like Apple and Samsung. The pump works seamlessly with any smartphone running on Android 7.0 or later, or iOS 12.2 or later.
In conclusion, the Medtronic MiniMed 780G insulin pump system is breaking new ground in diabetes management for individuals with Type 1 diabetes. With its hybrid closed-loop design, SmartGuard algorithm and meal detection technology the MiniMed 780G empowers users to effectively manage their blood glucose levels and reduce the risk of hypoglycemia. The pump’s customizable settings, real-time data and connectivity and compatibility with a wide range of smartphones make it a versatile and convenient tool for diabetes care. The recent FDA approval of the MiniMed 780G further solidifies its position as a reliable and trusted choice for insulin delivery. Overall the MiniMed 780G represents a transformative shift in diabetes care, enabling individuals to lead more flexible and fulfilling lives while instilling confidence in managing their condition.
This article was medically reviewed by Rachael Baker (BNg; CDE; MNgPrac)
Carlson, A.L., Sherr, J.L., Shulman, D.I., Garg, S.K., Pop-Busui, R., Bode, B.W., Lilenquist, D.R., Brazg, R.L., Kaiserman, K.B., Kipnes, M.S. and Thrasher, J.R., 2022. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technology & Therapeutics, 24(3), pp.178-189.
Silva, J.D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J. and Cohen, O., 2022. Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technology & Therapeutics, 24(2), pp.113-119.
Pintaudi, B., Gironi, I., Nicosia, R., Meneghini, E., Disoteo, O., Mion, E. and Bertuzzi, F., 2022. Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 32(7), pp.1719-1724.
Hartnell, S., Fuchs, J., Boughton, C.K. and Hovorka, R., 2021. Closed‐loop technology: a practical guide. Practical Diabetes, 38(4), pp.33-39.
Collyns, O.J., Meier, R.A., Betts, Z.L., Chan, D.S., Frampton, C., Frewen, C.M., Hewapathirana, N.M., Jones, S.D., Roy, A., Grosman, B. and Kurtz, N., 2021. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care, 44(4), pp.969-975.
Arrieta, A., Battelino, T., Scaramuzza, A.E., Da Silva, J., Castañeda, J., Cordero, T.L., Shin, J. and Cohen, O., 2022. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users. Diabetes, Obesity and Metabolism, 24(7), pp.1370-1379.
Lepore, G. et al. (2022) “Switching to the MinimedTM 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control,” Acta Diabetologica, 59(10), pp. 1309–1315. Available at: https://doi.org/10.1007/s00592-022-01937-5.
Battelino, T. et al. (2019) “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range,” Diabetes Care, 42(8), pp. 1593–1603. Available at: https://doi.org/10.2337/dci19-0028.
© Not Just a Patch 2023. Proudly created by AudsleyDesigns